PubMed · 16600658
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
P Rouger. 2006-04-04. [Formation-information].. https://doi.org/10.1016/j.tracli.2006.03.012
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
Isolated limb perfusion (ILP) is a treatment option for irresectable melanoma lesions, because with ILP 20-fold higher concentrations of chemotherapy can be achieved locally than is systemically possible and high response rates are subsequently achieved. Jehovah's witnesses do not accept any form of blood transfusion, either autologous or homologous blood or only blood products. The use of an extracorporeal circuit, without the use of any blood products is acceptable for Jehovah's witnesses. The case of a 59-year-old Jehovah's witness with an irresectable melanoma recurrence for which an ILP. Because of adequate blood flow through the perfused limb, the limb did not become acidotic, even though there was a significant drop in the Hb concentration in the limb during the ILP. Isolated limb perfusions without the use of any blood transfusion products are technically possible, but an adequate preoperative hemoglobin concentration is a prerequisite.
In 1996, due to a residual risk of transfusion-transmitted virus, a circular of the French Health Authorities (DGS/DH n degrees 96-609) recommended proposing to recipients of cellular blood products a test for antibodies to human immunodeficiency virus (HIV) and for antibodies to hepatitis C virus, before and three months after transfusion. We have evaluated the application of this recommendation throughout the whole transfused population of a French Hospital over a three month period. In addition, this study allowed us to establish the vaccination status against hepatitis B virus (HBV) infection in this exposed population including transfusion and nosocomial risks. The results showed a failure in the application of the 1996 circular and confirmed the validity of the abrogation of this circular by a recent circular (11 January 2006) of the French health authorities. It also showed that only a minority of patients needing a vaccination against HBV were afforded such treatment during their hospitalization.
The assessment of the viral residual risk from blood products is an assessment indicator of the quality management system and of the availability process of these products. Assessments of HIV, HBV and HCV viruses transmission risks through blood transfusion are calculated after the setting of a quality approach at the Abidjan NBTC. The method used estimates the risk of a donation made during a period immunologically silent. The residual risks for HIV, HBV, and HCV viruses have been estimated by multiplying the incidence rate for 100,000 people per year by the respective durations of the serological windows. The data received from the Abidjan Center's information processing system (Progesa 4.4d of MAK SYSTEM) go from 2002 to 2004 period. The residual risks are 1/5780 donations for HIV and 1/406 donations for the HCV, then 1/383 donations for the HBV. The residual risk for the HIV is almost four times reduced compared to that of 1997. The results show not only the importance of the transmission risk of HIV, HBV and HCV viruses through blood products, but also the necessity to set a quality management system in endemic countries of Sub-Saharan Africa.